PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS INSTRUCTIONS USE ONLY THE MOST CURRENT 59 MDW FORM 3039 AND

FOLLOW 59 MDWI 41-108 [http://static.e-publishing.af.mil/production/1/59mdw/publication/59mdwi41-108/59mdwi41-108.pdf] BOTH ON AF E-PUBLISHING

- The author must complete page two of this form. In Section 2, add the funding source for your study [e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SG5 O&M); SG5 R&D; Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP) ; Grants; etc.] Note: There may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, concerning any needed funding support.
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
- 3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- 5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
- 6. On page 2, have either your unit commander, program director or immediate supervisor:
 a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
- 7. Submit your completed form and all supporting documentation to the CRD for processing to: usaf.jbsa.59-mdw.mbx.wing-crd-publications-and-presentations@mail.mil. This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance. Note: Sending any material outside government control/oversight to meet a publication/presentation deadline, without PA clearing the material first, is considered releasing it to the public, which is in direct violation of applicable DoD and AF regulations/instructions.
- 8. The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
- 9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. **Note:** For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
- If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.
- 11. The Joint Ethics Regulation (JER) DoD 5500.07-R, *Standards of Conduct*, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check "NO" in block 17 of the Form 3039, your research or technical documents will not be forwarded to the 502 ISG/JAC legal office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.

If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

- "The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans: "The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02_AFI 40-402."
- NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP:

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23. Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966. as amended."

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS										
1. TO: CLINICAL RESEARCH 2. FROM: (Aut	hor's Name, Rank, Grade	e, Office Symbol)	3. GME/GHSE S	TUDENT: 4	A. PROTOCOL NUMBER:					
WingYee War	n, Capt, O3		YES 🗌	NO						
5. PROTOCOL TITLE: (NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039										
must be submitted for review and approval.)										
6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:										
Diabetes Champion Course #16: Overview of Complications: Chronic										
7. FUNDING RECEIVED FOR THIS STUDY? VES X NO FUNDING SOURCE:										
8. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES: 🔲 YES 🔀 NO										
9. IS THIS MATERIAL CLASSIFIED? 🗌 YES 🔀 NO										
10. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.?										
11. MATERIAL IS FOR: X DOMESTIC RELE										
CHECK APPROPRIATE BOX OR BOXES FOR APPROVAL WITH THIS REQUEST. ATTACH COPY OF MATERIAL TO BE PUBLISHED/PRESENTED. 11a. PUBLICATION/JOURNAL (List intended publication/journal.)										
11b. PUBLISHED ABSTRACT (List intended journal.)										
11c. POSTER (To be demonstrated at meeting: name of meeting, city, state, and date of meeting.)										
11d. PLATFORM PRESENTATION (At civilian institutions: name of meeting, state, and date of meting.) Diabetes Champion Course, WHASC, San Antonio, TX 7-10Apr2020										
11e. OTHER (Describe: name of meeting, city, state, and date of meeting.)										
12. HAVE YOUR ATTACHED RESEARCH/TEC	CHNICAL MATERIALS B	EEN PREVIOUSI Y APPROVE		HED/PRES	ENTED?					
		DATE								
DATE			on center (DTIC).							
7Apr2020										
-	/Last Namo, Eirst Namo	M L omail)		. DUTY PHONE/PAGER NUMBER						
14. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email) Morrow, Connie, C., connie.c.morrow.ctr@mail.mil					210-292-4414					
16. AUTHORSHIP AND CO-AUTHOR(S) List in the order they will appear in the manuscript. LAST NAME, FIRST NAME AND M.I. GRADE/RANK SQUADRON/GROUP/OFFICE SYMBOL INSTITUTION (If not 59 M										
a. Primary/Corresponding Author										
Wan, WingYee	O3/Capt	969 MDOS/SGO5E								
b.										
с.										
d.										
e.										
17. IS A 502 ISG/JAC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)? YES X NO										
I CERTIFY ANY HUMAN OR ANIMAL RESEARCH RELATED STUDIES WERE APPROVED AND PERFORMED IN STRICT ACCORDANCE WITH 32 CFR 219, AFMAN 40-401_IP, AND 59 MDWI 41-108. I HAVE READ THE FINAL VERSION OF THE ATTACHED MATERIAL AND CERTIFY THAT IT IS AN ACCURATE MANUSCRIPT FOR PUBLICATION AND/OR PRESENTATION.										
18. AUTHOR'S PRINTED NAME, RANK, GRAD WingYee Wan, Capt, O3		19. AUTHOR'S SIGNATURE		20. DATE 12Feb2020						
21. APPROVING AUTHORITY'S PRINTED NA VERONICA B. VALERIO, Maj, USAF, N	22. APPROVING AUT			23. DATE February 13, 2020						
59 MDW FORM 3039 10 JULY 2018 PREVIOUS EDITIONS ARE OBSOLETE Page 2 of 3 Pages										

PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS								
1st ENDORSEMENT (59 MDW/SGVU Use C			-					
TO: Clinical Research Division 59 MDW/CRD	24. DATE RECEIVED		25. ASSIGNED PRO	OCESSING REQUEST FILE N	UMBER			
Contact 292-7141 for email instructions.	February 13, 2020							
26. DATE REVIEWED			27. DATE FORWAR	DED TO 502 ISG/JAC				
February 13, 2020								
28. AUTHOR CONTACTED FOR RECOMM	ENDED OR NECESSAR	Y CHANGE	es: 🛛 NO 🗌 yes	If yes, give date.	N/A			
29. COMMENTS 🔀 APPROVED 🗌 DI	SAPPROVED							
30. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER			31. REVIEWER SIGN	IATURE	32. DATE			
Paul T. Barnicott, GS-15, Dep Dir, 59 MDW/STC					February 13, 2020			
2nd ENDORSEMENT (502 ISG/JAC Use Or					, , , , , , , , , ,			
33. DATE RECEIVED			34. DATE FORWARDED TO 59 MDW/PA					
					29. DATE			
36. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER		37. REVIEWER SIGN	ATURE	38. DATE			
3rd ENDORSEMENT (59 MDW/PA Use Only	y)							
39. DATE RECEIVED								
41. COMMENTS APPROVED (In compliance with security and policy review directives.) DISAPPROVED								
42. PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER			43. REVIEWER SIGNATURE		44. DATE			
4th ENDORSEMENT (59 MDW/SGVU Use 0	Only)				1			
45. DATE RECEIVED		46. SENIO		D BY PHONE OF APPROVAL	OR DISAPPROVAL EFT MESSAGE			
47. COMMENTS APPROVED DI	SAPPROVED							
48. PRINTED NAME, RANK/GRADE, TITLE	.E OF REVIEWER		49. REVIEWER SIGNATURE		50. DATE			
59 MDW FORM 3039 10 JULY 201	8 PREVIOU	IS EDITION	IS ARE OBSOLETE		Page 3 of 3 Pages			